gene therapy sarepta - Search News

News

Sarepta Will Resume Gene Therapy Shipments

Reuters on MSN · 2d

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

The Associated Press on MSN · 2d

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Fierce Pharma · 1d

Vinay Prasad departs FDA amid conservative criticism, controversy over Sarepta gene therapy

Vinay Prasad, M.D., has left the FDA less than three months into the role as director of the Center for Biologics Evaluation and Research (CBER), overseeing vaccines and cell and gene therapies.

6don MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...

1d

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results